West Oak Capital’s Editas Medicine EDIT Stock Holding History

West Oak Capital’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25	Closed	–	–	340
2022 Q1	$0	Hold	25	–	–	﹤0.01%	368
2021 Q4	$1K	Buy	+25	New	+$860	﹤0.01%	335

Other funds holding EDIT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

West Oak Capital's EDIT Position: Q2 2022 in Review

West Oak Capital sold out of Editas Medicine (EDIT) in Q2 2022, closing a stake of 25 shares.

West Oak Capital first reported a position in EDIT in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q4 2021. 256 funds tracked by Wall St. Rank hold EDIT as of Q2 2022.

West Oak Capital reported no remaining Editas Medicine position as of Q2 2022 after selling out during the quarter.
West Oak Capital sold 25 Editas Medicine shares in Q2 2022.
West Oak Capital first reported a position in Editas Medicine in Q4 2021 and held it in 2 quarters.
West Oak Capital's Editas Medicine position peaked at $1K in Q4 2021.
256 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2022.

Based on West Oak Capital's 13F filing for Q2 2022, filed 11 Jul 2022.